Pirtobrutinib with standard chemo for untreated lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new targeted therapy (pirtobrutinib) added to standard chemotherapy for a specific type of lymphoma. It aims to see if the combination improves outcomes for patients who have not been treated before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lymphoma called non-GCB diffuse large B-cell lymphoma (DLBCL).
- You are between 18 and 80 years old.
- You have not received any previous treatment for lymphoma.
- Your overall health is good enough (able to care for yourself, out of bed more than half the day).
- You have adequate organ function, such as kidneys, liver, and heart.
- You are not pregnant and agree to use effective contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs for a certain type of lymphoma (non-GCB DLBCL). The drugs are pirtobrutinib (a targeted pill) plus a standard chemotherapy regimen called Pola-R-CHP. The goal is to see if adding this targeted therapy improves outcomes for people with this specific subtype.
This trial tests a combination of three drugs—pirtobrutinib, lisaftoclax, and rituximab—for people with relapsed or refractory DLBCL who have already had at least one prior treatment. The goal is to see if this combination can help shrink or control the lymphoma.
This trial tests a combination of targeted therapy (Orelabrutinib) plus standard chemotherapy (Pola-R-CHP) for people with untreated non-GCB diffuse large B-cell lymphoma. The goal is to see if this new mix works better than the usual treatment.
This trial tests a combination of targeted drugs for people with a type of lymphoma (DLBCL) that has come back or not responded after previous treatment with a BTK inhibitor. The goal is to see if adding a drug called pirtobrutinib to standard chemotherapy helps control the cancer.
This trial tests a new combination: zanubrutinib (a targeted pill) plus standard chemotherapy (R-CHOP) for people newly diagnosed with DLBCL whose cancer cells have high p53 protein levels. The goal is to see if adding this drug helps shrink tumors better than chemotherapy alone.
This trial tests a combination of two drugs (pirtobrutinib and chemotherapy given for a short time) to treat chronic lymphocytic leukemia (CLL) in patients who have never been treated before. The goal is to see if this approach works well and can be given for a fixed, shorter duration than traditional treatments.
Hear when a new DLBCL - Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.